Compositions and methods of treatment with stem cells
OwnerKeith Leonard March, Carmella Evans Molinainventors
Life of this patent
Estimating the term…
Abstract
The disclosure of the present application provides compositions and methods of treatment with stem cells. In at least one embodiment of a method for treating a patient with an insulin-related disorder, the method comprises the step of administering a cell-based composition to a patient with an insulin-related disorder to treat the insulin-related disorder, the cell-based composition comprising at least one mammalian stem cell and optionally at least one islet cell, the at least one mammalian stem cell capable of prolonging an effective life of the at least one islet cell.
Claims30
A method for treating a patient with an insulin-related disorder, the method comprising the step of:
- administering a cell-based composition to a patient with an insulin-related disorder to treat the insulin-related disorder, the cell-based composition comprising at least one mammalian stem cell and at least one islet cell, the at least one mammalian stem cell capable of prolonging an effective life of the at least one islet cell.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A method for treating a patient with an insulin-related disorder, the method comprising the step of:
- administering a cell-based composition to a patient with an insulin-related disorder to treat the insulin-related disorder, the cell-based composition comprising at least one mammalian stem cell and at least one islet cell, the at least one mammalian stem cell capable of prolonging an effective life of the at least one islet cell and further capable of effectuating promotion of insulin production within the patient.
21-26. (canceled)
29-39. (canceled)
A method for treating a patient with an insulin-related disorder, the method comprising the step of:
- administering a cell-based composition to a patient with an insulin-related disorder to treat the insulin-related disorder, the cell-based composition comprising at least one mammalian stem cell capable of effectuating promotion of insulin production within the patient.
41-43. (canceled)
45-74. (canceled)
76-84. (canceled)
Dependencies are inferred from the claim text.